Nadroparin
From Wikipedia, the free encyclopedia
|
Nadroparin
|
|
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | B01 |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | Mean MW = 4500 Daltons |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Nadroparin is a form of low molecular weight heparin.
[edit] References
- The Merck Index, 12th Edition. 6434
[edit] External links
- http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=483128
- http://www.mayoclinic.com/health/drug-information/DR600971
- Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A (2006). "A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study". Pharmacology 78 (3): 136–43. doi:. PMID 17057417.

